Mounjaro heart label helps diabetes coverage, not obesity coverage, analysts say

The Food and Drug Administration expanded the label for Mounjaro (tirzepatide) on August 28, 2026, adding reduction of cardiovascular death, heart attack and stroke risk in adults with type 2 diabetes who are at high cardiovascular risk ^[1]. A 24/7 Wall St. analysis argues the new wording is likely to help in diabetes coverage negotiations but does not reach Zepbound, Lilly's obesity brand, which is where employer coverage is shrinking fastest ^[1].

The supporting trial enrolled more than 13,000 patients and found 8% fewer major cardiovascular events with Mounjaro than with Lilly's older Trulicity ^[1]. Because that comparison was against another active GLP-1 rather than a placebo, the analysis says it shows Mounjaro edging out an established therapy rather than proving the drug class saves lives from a standing start ^[1]. The approval is a diabetes indication; Zepbound's obesity label was not changed ^[1].

Employer coverage of GLP-1 weight-loss drugs fell from 72% in 2025 to 60% in 2026, and about 14% of surveyed employers have already dropped the medicines or plan to drop them in 2027 ^[1][2]. That figure reflects what benefits managers say they intend to offer at renewal, not what patients end up using, and such plans can reverse when employees object ^[2].

Lilly's second-quarter revenue reached $22.97 billion, up 47.67% from a year earlier ^[2]. Mounjaro brought in $9.94 billion, up 91%, with U.S. growth of 45% and international growth of 172% after China added the drug to its national reimbursement list ^[1]. Zepbound produced $4.93 billion ^[2]. Lilly raised full-year guidance to $85.0 billion to $87.0 billion, and CEO David Ricks said, "Lilly's momentum continues, as we delivered 48% revenue growth and raised our full-year guidance" ^[1].

The two accounts of the quarter describe pricing differently. One puts the U.S. price decline at 9% excluding rebate adjustments ^[1]; the other describes a 13% decrease in realized prices that was more than offset by a 60% increase in volume ^[2]. CFO Lucas Montarce told investors, "expect that price will actually go down for sure … we are going to more than offset that with volume growth" ^[1].

Direct-pay channels are part of that picture. About 45% of all Zepbound prescriptions and 55% of new Zepbound prescriptions were self-pay in the quarter ^[2]. Lilly Employer Connect offers Zepbound at $449 per month across all doses through participating programs ^[2], and the Medicare GLP-1 Bridge Program is described as covering 20 million eligible Americans at $50 per month ^[1].

Why it matters for patients

A label expansion does not compel any insurer or employer to pay for anything ^[1]. For a person with type 2 diabetes and high cardiovascular risk, the new Mounjaro wording gives a health plan a documented reason to keep covering the drug during a cost review ^[1]. For a person taking Zepbound for weight loss, this approval changes nothing about whether an employer plan covers it ^[1].

When an employer drops a drug category, patient out-of-pocket costs rise sharply and prescriptions can shift toward cash-pay channels ^[2]. Whether any specific insurer or employer has changed its coverage because of the August 28 approval has not been reported. The companies' list prices, rebates and individual plan formularies are also not disclosed in these accounts.

What happens next

Coverage decisions take effect at renewal, so the 14% figure reflects employer intentions for 2027 rather than signed contracts ^[2]. The analysis adds that the label's value depends on whether Lilly can convert it into contract language rather than announcements ^[1]. Lilly shares traded at $1,174.61 and were down 6.44% over the previous week, which the authors read as the market not yet treating the cardiovascular claim as a coverage shield; an analyst price target of $1,315.04 was cited ^[1].

Whether Lilly's diabetes argument changes any payer's written policy is not yet known.